Cargando…

In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani

BACKGROUND: Visceral Leishmaniasis (VL) is a fatal vector-borne parasitic disorder occurring mainly in tropical and subtropical regions. VL falls under the category of neglected tropical diseases with growing drug resistance and lacking a licensed vaccine. Conventional vaccine synthesis techniques a...

Descripción completa

Detalles Bibliográficos
Autores principales: Saha, Subhadip, Vashishtha, Shubham, Kundu, Bishwajit, Ghosh, Monidipa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354309/
https://www.ncbi.nlm.nih.gov/pubmed/35931960
http://dx.doi.org/10.1186/s12859-022-04816-6
_version_ 1784763040038649856
author Saha, Subhadip
Vashishtha, Shubham
Kundu, Bishwajit
Ghosh, Monidipa
author_facet Saha, Subhadip
Vashishtha, Shubham
Kundu, Bishwajit
Ghosh, Monidipa
author_sort Saha, Subhadip
collection PubMed
description BACKGROUND: Visceral Leishmaniasis (VL) is a fatal vector-borne parasitic disorder occurring mainly in tropical and subtropical regions. VL falls under the category of neglected tropical diseases with growing drug resistance and lacking a licensed vaccine. Conventional vaccine synthesis techniques are often very laborious and challenging. With the advancement of bioinformatics and its application in immunology, it is now more convenient to design multi-epitope vaccines comprising predicted immuno-dominant epitopes of multiple antigenic proteins. We have chosen four antigenic proteins of Leishmania donovani and identified their T-cell and B-cell epitopes, utilizing those for in-silico chimeric vaccine designing. The various physicochemical characteristics of the vaccine have been explored and the tertiary structure of the chimeric construct is predicted to perform docking studies and molecular dynamics simulations. RESULTS: The vaccine construct is generated by joining the epitopes with specific linkers. The predicted tertiary structure of the vaccine has been found to be valid and docking studies reveal the construct shows a high affinity towards the TLR-4 receptor. Population coverage analysis shows the vaccine can be effective on the majority of the world population. In-silico immune simulation studies confirms the vaccine to raise a pro-inflammatory response with the proliferation of activated T and B cells. In-silico codon optimization and cloning of the vaccine nucleic acid sequence have also been achieved in the pET28a vector. CONCLUSION: The above bioinformatics data support that the construct may act as a potential vaccine. Further wet lab synthesis of the vaccine and in vivo works has to be undertaken in animal model to confirm vaccine potency. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-022-04816-6.
format Online
Article
Text
id pubmed-9354309
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93543092022-08-06 In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani Saha, Subhadip Vashishtha, Shubham Kundu, Bishwajit Ghosh, Monidipa BMC Bioinformatics Research BACKGROUND: Visceral Leishmaniasis (VL) is a fatal vector-borne parasitic disorder occurring mainly in tropical and subtropical regions. VL falls under the category of neglected tropical diseases with growing drug resistance and lacking a licensed vaccine. Conventional vaccine synthesis techniques are often very laborious and challenging. With the advancement of bioinformatics and its application in immunology, it is now more convenient to design multi-epitope vaccines comprising predicted immuno-dominant epitopes of multiple antigenic proteins. We have chosen four antigenic proteins of Leishmania donovani and identified their T-cell and B-cell epitopes, utilizing those for in-silico chimeric vaccine designing. The various physicochemical characteristics of the vaccine have been explored and the tertiary structure of the chimeric construct is predicted to perform docking studies and molecular dynamics simulations. RESULTS: The vaccine construct is generated by joining the epitopes with specific linkers. The predicted tertiary structure of the vaccine has been found to be valid and docking studies reveal the construct shows a high affinity towards the TLR-4 receptor. Population coverage analysis shows the vaccine can be effective on the majority of the world population. In-silico immune simulation studies confirms the vaccine to raise a pro-inflammatory response with the proliferation of activated T and B cells. In-silico codon optimization and cloning of the vaccine nucleic acid sequence have also been achieved in the pET28a vector. CONCLUSION: The above bioinformatics data support that the construct may act as a potential vaccine. Further wet lab synthesis of the vaccine and in vivo works has to be undertaken in animal model to confirm vaccine potency. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-022-04816-6. BioMed Central 2022-08-05 /pmc/articles/PMC9354309/ /pubmed/35931960 http://dx.doi.org/10.1186/s12859-022-04816-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Saha, Subhadip
Vashishtha, Shubham
Kundu, Bishwajit
Ghosh, Monidipa
In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani
title In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani
title_full In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani
title_fullStr In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani
title_full_unstemmed In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani
title_short In-silico design of an immunoinformatics based multi-epitope vaccine against Leishmania donovani
title_sort in-silico design of an immunoinformatics based multi-epitope vaccine against leishmania donovani
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354309/
https://www.ncbi.nlm.nih.gov/pubmed/35931960
http://dx.doi.org/10.1186/s12859-022-04816-6
work_keys_str_mv AT sahasubhadip insilicodesignofanimmunoinformaticsbasedmultiepitopevaccineagainstleishmaniadonovani
AT vashishthashubham insilicodesignofanimmunoinformaticsbasedmultiepitopevaccineagainstleishmaniadonovani
AT kundubishwajit insilicodesignofanimmunoinformaticsbasedmultiepitopevaccineagainstleishmaniadonovani
AT ghoshmonidipa insilicodesignofanimmunoinformaticsbasedmultiepitopevaccineagainstleishmaniadonovani